3T Biosciences Expands Leadership Team With Bryan Irving, Ph.D., as Chief Scientific Officer to Progress Tumor-specific Therapies to Clinic
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 /PRNewswire/ -- 3T Biosciences ("3T"), an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of Bryan Irving, Ph.D., as chief scientific officer (CSO). In this role, Dr. Irving will be responsible for the company's scientific strategy and direction and will chair 3T's Scientific Advisory Board.
- In this role, Dr. Irving will be responsible for the company's scientific strategy and direction and will chair 3T's Scientific Advisory Board.
- His work has focused primarily on exploring ways to modulate T-cell activity for therapeutic benefit in both oncology and autoimmune settings.
- "3T shares my passion for innovation and has a culture of rigor and dedication to advancing novel therapies.
- 3T Biosciences is an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response-guided target discovery approach.